Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view

Frederick W. Thielen(University Medical Center Freiburg), Annemieke van Dongen‐Leunis(Erasmus University Rotterdam), Alexander M. M. Arons(Novartis (Netherlands)), Judith R. Ladestein(Novartis (Netherlands)), Peter M. Hoogerbrugge(Helios Klinikum Emil von Behring)
European Journal Of Haematology
April 14, 2020
Cited by 42


Related Papers